We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

65 hedge funds and large institutions have $40.1M invested in Palvella Therapeutics in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 21 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more call options, than puts

Call options by funds: $126K | Put options by funds: $18K

0.04% less ownership

Funds ownership: 0.63% → 0.59% (-0.04%)

4% less funds holding

Funds holding: 68 → 65 (-3)

29% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 7

38% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 21

41% less capital invested

Capital invested by funds: $68.3M → $40.1M (-$28.2M)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
65
Holders Change
-3
Holders Change %
-4.41%
% of All Funds
1.12%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
5
Increased
13
Reduced
21
Closed
7
Calls
$126K
Puts
$18K
Net Calls
+$108K
Net Calls Change
-$90K

Top Buyers

1
ACM
Aquilo Capital Management
California
+$483K
2
LCM
Lynx1 Capital Management
Puerto Rico
+$470K
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$385K
4
Renaissance Technologies
Renaissance Technologies
New York
+$243K
5
PIM
Platinum Investment Management
Australia
+$196K

Top Sellers

1
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$1.93M
2
GPP
Great Point Partners
Connecticut
-$882K
3
Citigroup
Citigroup
New York
-$556K
4
XT
XTX Topco
Cayman Islands
-$186K
5
Millennium Management
Millennium Management
New York
-$185K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$5.84M – – –
SCM
2
Soleus Capital Management
Connecticut
$4.75M – – –
ACM
3
Aquilo Capital Management
California
$4.64M +$483K +3,750 +8%
LCM
4
Lynx1 Capital Management
Puerto Rico
$4.04M +$470K +3,647 +9%
Marshall Wace
5
Marshall Wace
United Kingdom
$2.81M -$143K -1,106 -3%
Citadel Advisors
6
Citadel Advisors
Florida
$2.35M +$43.4K +337 +1%
GPP
7
Great Point Partners
Connecticut
$2.26M -$882K -6,838 -22%
BlackRock
8
BlackRock
New York
$1.53M -$14.6K -113 -0.7%
PIM
9
Platinum Investment Management
Australia
$1.4M +$196K +1,524 +11%
Morgan Stanley
10
Morgan Stanley
New York
$1.33M -$19.5K -151 -1%
Vanguard Group
11
Vanguard Group
Pennsylvania
$1.22M – – –
CS
12
Candriam SCA
Luxembourg
$1.22M – – –
Acadian Asset Management
13
Acadian Asset Management
Massachusetts
$874K -$58.4K -453 -5%
Renaissance Technologies
14
Renaissance Technologies
New York
$841K +$243K +1,888 +26%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$726K +$1.55K +12 +0.2%
Bank of America
16
Bank of America
North Carolina
$611K -$53.9K -418 -6%
CCB
17
Cutter & Co Brokerage
Missouri
$468K -$9.15K -71 -1%
Jacobs Levy Equity Management
18
Jacobs Levy Equity Management
New Jersey
$452K +$385K +2,987 +155%
SPC
19
Sigma Planning Corp
Michigan
$363K +$387 +3 +0.1%
State Street
20
State Street
Massachusetts
$241K – – –
Millennium Management
21
Millennium Management
New York
$178K -$185K -1,433 -43%
Connor, Clark & Lunn Investment Management (CC&L)
22
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$154K +$72.8K +565 +51%
Fidelity Investments
23
Fidelity Investments
Massachusetts
$144K – – –
Cerity Partners
24
Cerity Partners
New York
$138K – – –
BCM
25
Bridgeway Capital Management
Texas
$134K -$156K -1,208 -45%
1
2 3

PVLA Hedge Fund Activity: Q3 2022 in Review

65 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q3 2022, worth a combined $40.1M — down 41% from $68.3M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of PVLA and 5 opened new positions — a net loss of 2 holders — while 21 trimmed existing stakes and 13 added.

The largest buyer was Aquilo Capital Management, adding an estimated $483K. The largest seller was Assenagon Asset Management, cutting an estimated $1.93M.

  • 65 institutional investors held Palvella Therapeutics (PVLA) as of Q3 2022, down from 68 in Q2 2022.
  • Funds reported $40.1M of Palvella Therapeutics stock for Q3 2022, down 41% quarter-over-quarter.
  • 5 funds opened new Palvella Therapeutics positions in Q3 2022 and 7 closed out, a net change of -2 holders.
  • The largest Palvella Therapeutics buyer in Q3 2022 was Aquilo Capital Management, an estimated $483K added.
  • The largest Palvella Therapeutics seller in Q3 2022 was Assenagon Asset Management, an estimated $1.93M sold.

Based on aggregated 13F filings for Q3 2022.